Lipodystrophy - Unveiling the Future: A Comprehensive Epidemiology Forecast Report to 2032


Dublin, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The "Lipodystrophy Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

This comprehensive report provides an in-depth understanding of Lipodystrophy, covering historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Lipodystrophy: An Overview

Lipodystrophy is a medical condition characterized by the partial or complete loss of adipose tissue. Often, this condition is accompanied by the pathological accumulation of adipose tissue in specific anatomical areas. Patients with lipodystrophy experience metabolic complications, highlighting the significance of adipose tissue as an active endocrine organ. Ongoing genetic and molecular research has provided valuable insights into the mechanisms underlying lipodystrophy, enabling the development of novel therapeutic approaches.

Types of Lipodystrophy

Lipodystrophies are classified based on their etiology (congenital or acquired) and the pattern of adipose tissue loss (generalized or partial).

  1. Congenital Generalized Lipodystrophy (CGL) - Also known as Berardinelli-Seip syndrome, CGL is a rare autosomal recessive disorder characterized by a near-total lack of body adipose tissue. Patients with CGL may present with various metabolic complications, including diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and more.
  2. Acquired Generalized Lipodystrophy - Known as Lawrence-Seip syndrome, this form of lipodystrophy shares features with CGL but is acquired rather than congenital. It is associated with severely reduced subcutaneous adiposity, insulin resistance, acanthosis nigricans, and other metabolic abnormalities.

Key Findings

The report presents key findings based on epidemiological data and forecasting:

  1. In 2021, the total incident cases of Lipodystrophy in the US were ~1,050 cases, projected to increase by 2032.
  2. EU4 and the UK accounted for ~1,850 cases of Lipodystrophy in 2021, expected to rise by 2032. France exhibited the highest number of cases among the EU4 countries, with ~760 cases in 2021, estimated to increase by 2032.
  3. In 2021, the gender-specific cases of Lipodystrophy in the US were ~210 for males and ~840 for females. These cases are expected to grow during the forecast period.

Scope of the Report

The report covers a descriptive overview of Lipodystrophy, explaining its procedure, types, and indications. It provides insight into the historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also assesses the risk and burden of Lipodystrophy and provides segmentation of the epidemiology for 7MM by Total Cases of Lipodystrophy, Subtype-specific Cases of Lipodystrophy, and Gender-specific Cases of Lipodystrophy.

For a detailed analysis and insights into the Lipodystrophy epidemiology forecast visit https://www.researchandmarkets.com/r/htyu06

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Coordonnées